| Description | (Z)-KC02 is an ABHD16A inhibitor which targets the enzyme responsible for producing lysophosphatidylserine (lyso-PS), a lipid involved in regulating immune and neurological functions. This compound is linked to the mitigation of neurological disorders, including retinitis pigmentosa and cataracts (PHARC), by depleting lyso-PS in lymphoblasts from affected individuals. Moreover, (Z)-KC02 diminishes lyso-PS levels and lipopolysaccharide-induced cytokine production in macrophages and influences lyso-PS metabolism in vivo [1]. |
| In vitro | (Z)-KC02 通过在小鼠巨噬细胞中破坏 ABHD16A 来降低 lyso-PS 水平[1]。 |
| molecular weight | 287.35 |
| Molecular formula | C17H21NO3 |
| CAS | 1646795-60-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |